Chinese Journal of Dermatology ›› 2017, Vol. 50 ›› Issue (2): 138-141.
Previous Articles Next Articles
Received:2017-01-12
Revised:2017-01-20
Online:2017-02-15
Published:2017-01-24
Contact:
WANG Gang
E-mail:xjwgang@fmmu.edu.cn
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
| ［1］ | Deng Y, Chang C, Lu Q. The inflammatory response in psoriasis: a comprehensive review［J］. Clin Rev Allergy Immunol, 2016, 50（3）: 377⁃389. DOI: 10.1007/s12016⁃016⁃8535⁃x. |
| ［2］ | Sticherling M. Psoriasis and autoimmunity［J］. Autoimmun Rev, 2016, 15（12）: 1167⁃1170. DOI: 10.1016/j.autrev.2016.09.004. |
| ［3］ | Grant CR, Liberal R, Mieli⁃Vergani G, et al. Regulatory T⁃cells in autoimmune diseases: challenges, controversies and⁃⁃yet⁃⁃unanswered questions［J］. Autoimmun Rev, 2015, 14（2）: 105⁃116. DOI: 10.1016/j.autrev.2014.10.012. |
| ［4］ | Bovenschen HJ, van de Kerkhof PC, van Erp PE, et al. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL⁃17A⁃producing cells and are found in lesional skin［J］. J Invest Dermatol, 2011, 131（9）: 1853⁃1860. DOI: 10.1038/jid.2011.139. |
| ［5］ | Ganguly D, Haak S, Sisirak V, et al. The role of dendritic cells in autoimmunity［J］. Nat Rev Immunol, 2013, 13（8）: 566⁃577. DOI: 10.1038/nri3477. |
| ［6］ | Haniffa M, Gunawan M, Jardine L. Human skin dendritic cells in health and disease［J］. J Dermatol Sci, 2015, 77（2）: 85⁃92. DOI: 10.1016/j.jdermsci.2014.08.012. |
| ［7］ | Martini E, Wiken M, Cheuk S, et al. Dynamic changes in resident and infiltrating epidermal dendritic cells in active and resolved psoriasis［J］. J Invest Dermatol, 2016. DOI: 10.1016/j.jid.2016.11.033. |
| ［8］ | Singh TP, Zhang HH, Borek I, et al. Monocyte⁃derived inflam⁃matory Langerhans cells and dermal dendritic cells mediate psoriasis⁃like inflammation［J］. Nat Commun, 2016, 7: 13581. DOI: 10.1038/ncomms13581. |
| ［9］ | Kim J, Krueger JG. Highly effective new treatments for psoriasis target the IL⁃23/Type 17 T cell autoimmune Axis［J］. Annu Rev Med, 2017, 68: 255⁃269. DOI: 10.1146/annurev⁃med⁃042915⁃103905. |
| ［10］ | Brinkmann V, Zychlinsky A. Neutrophil extracellular traps: is immunity the second function of chromatin?［J］. J Cell Biol, 2012, 198（5）: 773⁃783. DOI: 10.1083/jcb.201203170. |
| ［11］ | Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL⁃17 through extracellular trap formation in psoriasis［J］. J Immunol, 2011, 187（1）: 490⁃500. DOI: 10.4049/jimmunol. 1100123. |
| ［12］ | Hu SC, Yu HS, Yen FL, et al. Neutrophil extracellular trap forma⁃tion is increased in psoriasis and induces human β⁃defensin⁃2 production in epidermal keratinocytes［J］. Sci Rep, 2016, 6: 31119. DOI: 10.1038/srep31119. |
| ［13］ | Li N, Yamasaki K, Saito R, et al. Alarmin function of cathelicidin antimicrobial peptide LL37 through IL⁃36γ induction in human epidermal keratinocytes［J］. J Immunol, 2014, 193（10）: 5140⁃5148. DOI: 10.4049/jimmunol.1302574. |
| ［14］ | Shao S, Cao T, Jin L, et al. Increased lipocalin⁃2 contributes to the pathogenesis of psoriasis by modulating neutrophil chemotaxis and cytokine secretion［J］. J Invest Dermatol, 2016, 136（7）: 1418⁃1428. DOI: 10.1016/j.jid.2016.03.002. |
| ［15］ | Boehncke WH, Schön MP. Psoriasis［J］. Lancet, 2015, 386（9997）: 983⁃994. DOI: 10.1016/S0140⁃6736（14）61909⁃7. |
| ［16］ | Krueger JG. An autoimmune "attack" on melanocytes triggers psoriasis and cellular hyperplasia［J］. J Exp Med, 2015, 212（13）: 2186. DOI: 10.1084/jem.21213insight3. |
| ［17］ | Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review［J］. J Autoimmun, 2015, 64: 66⁃73. DOI: 10.1016/j.jaut.2015.07.008. |
| ［18］ | Zhou F, Cao H, Zuo X, et al. Deep sequencing of the MHC region in the Chinese population contributes to studies of complex disease［J］. Nat Genet, 2016, 48（7）: 740⁃746. DOI: 10.1038/ng.3576. |
| ［19］ | Zhang LJ, Sen GL, Ward NL, et al. Antimicrobial peptide LL37 and MAVS signaling drive interferon⁃β production by epidermal keratinocytes during skin Injury［J］. Immunity, 2016, 45（1）: 119⁃130. DOI: 10.1016/j.immuni.2016.06.021. |
| ［20］ | Lande R, Botti E, Jandus C, et al. The antimicrobial peptide LL37 is a T⁃cell autoantigen in psoriasis［J］. Nat Commun, 2014, 5: 5621. DOI: 10.1038/ncomms6621. |
| ［21］ | Arakawa A, Siewert K, Stöhr J, et al. Melanocyte antigen triggers autoimmunity in human psoriasis［J］. J Exp Med, 2015, 212（13）: 2203⁃2212. DOI: 10.1084/jem.20151093. |
| ［22］ | Shen Z, Wang G, Fan JY, et al. HLA DR B1*04, *07⁃restricted epitopes on keratin 17 for autoreactive T cells in psoriasis［J］. J Dermatol Sci, 2005, 38（1）: 25⁃39. DOI: 10.1016/j.jdermsci.2005. 01.001. |
| ［23］ | Jin L, Wang G. Keratin 17: a critical player in the pathogenesis of psoriasis［J］. Med Res Rev, 2014, 34（2）: 438⁃454. DOI: 10.1002/med.21291. |
| ［24］ | Shen Z, Chen L, Liu YF, et al. Altered keratin 17 peptide ligands inhibit in vitro proliferation of keratinocytes and T cells isolated from patients with psoriasis［J］. J Am Acad Dermatol, 2006, 54（6）: 992⁃1002. DOI: 10.1016/j.jaad.2006.02.033. |
| ［25］ | Fragoulis GE, Siebert S, McInnes IB. Therapeutic targeting of IL⁃17 and IL⁃23 cytokines in immune⁃mediated diseases［J］. Annu Rev Med, 2016, 67: 337⁃353. DOI: 10.1146/annurev⁃med⁃051914⁃021944. |
| ［26］ | Kimball AB, Papp KA, Wasfi Y, et al. Long⁃term efficacy of ustekinumab in patients with moderate⁃to⁃severe psoriasis treated for up to 5 years in the PHOENIX 1 study［J］. J Eur Acad Dermatol Venereol, 2013, 27（12）: 1535⁃1545. DOI: 10.1111/jdv.12046. |
| ［27］ | Valenzuela F, Paul C, Mallbris L, et al. Tofacitinib versus etaner⁃cept or placebo in patients with moderate to severe chronic plaque psoriasis: patient⁃reported outcomes from a Phase 3 study［J］. J Eur Acad Dermatol Venereol, 2016, 30（10）: 1753⁃1759. DOI: 10.1111/jdv.13702. |
| ［28］ | Papp KA, Bissonnette R, Gooderham M, et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial［J］. BMC Dermatol, 2016, 16（1）: 15. DOI: 10.1186/s12895⁃016⁃0051⁃4. |
| ［29］ | Del RJQ, Kircik L. Oral apremilast for the treatment of plaque psoriasis［J］. J Clin Aesthet Dermatol, 2016, 9（9）: 43⁃48. |
| ［30］ | Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase （JAK） 1/JAK2 inhibitor, in patients with moderate⁃to⁃severe psoriasis［J］. Br J Dermatol, 2016, 174（6）: 1266⁃1276. DOI: 10.1111/bjd.14403. |
| ［31］ | Greb JE, Goldminz AM, Elder JT, et al. Psoriasis［J］. Nat Rev Dis Primers, 2016, 2: 16082. DOI: 10.1038/nrdp.2016.82. |
| ［32］ | Linares⁃Pineda TM, Cañadas⁃Garre M, Sánchez⁃Pozo A, et al. Gene polymorphisms as predictors of response to biological therapies in psoriasis patients［J］. Pharmacol Res, 2016, 113（Pt A）: 71⁃80. DOI: 10.1016/j.phrs.2016.07.020. |
| ［33］ | van den Reek JM, Coenen MJ, van de L'Isle Arias M, et al. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis［J］. Br J Dermatol, 2016. DOI: 10.1111/bjd.15005. |
| ［34］ | Białecka M, Ostasz R, Kurzawski M, et al. IL17A and IL17F gene polymorphism association with psoriasis risk and response to treatment in a polish population［J］. Dermatology, 2016, 232（5）: 592⁃596. DOI: 10.1159/000448090. |
| ［35］ | Gallo E, Cabaleiro T, Román M, et al. The relationship between tumour necrosis factor （TNF）⁃α promoter and IL12B/IL⁃23R genes polymorphisms and the efficacy of anti⁃TNF⁃α therapy in psoriasis: a case⁃control study［J］. Br J Dermatol, 2013, 169（4）: 819⁃829. DOI: 10.1111/bjd.12425. |
| No related articles found! |
|
